Anthropic Reveals In-House Drug Development Programs Using Claude for Cancer and Rare Diseases
Sign in✓ Signed in
Anthropic disclosed on Monday that it is developing its own experimental drug candidates using Claude, advancing work begun through partnerships with six pharmaceutical and biotechnology organizations. The AI company has established internal programs targeting rare childhood diseases and various forms of cancer, complementing research collaborations announced earlier in 2026.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...